Are clinical trajectories in obstructive hypertrophic cardiomyopathy mutation-specific? A systematic review and meta-analysis of MYH7 vs. MYBPC3
Frontiers in Cardiovascular Medicine · 29.04.2026 · 13
DOI: 10.3389/fcvm.2026.1752303 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 29.04.2026. Verfasst von Yunqing Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The clinical course of obstructive hypertrophic cardiomyopathy (HCM) is highly variable. Whether this heterogeneity reflects mutation-specific clinical trajectories remains a pivotal question for prognostication and personalized management.
Objectives
This study aimed to determine if pathogenic sarcomeric variants in MYH7 and MYBPC3 are associated with distinct clinical pathways in obstructive HCM, by comparing their associations with age at presentation, severity of hypertrophy, left ventricular outflow tract (LVOT) obstruction, and arrhythmic outcomes.
Methods
We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. Four databases were searched up to October 2025 for cohort or registry studies reporting on sarcomeric variants and quantitative phenotypes in obstructive HCM. Data were extracted independently in duplicate, and effect estimates were pooled as odds ratios (OR), mean differences (MD), or hazard ratios (HR) with 95% confidence intervals (CI).
Results
Ten studies comprising 192,361 participants were included, encompassing a large population sequencing cohort (UK Biobank/Mass General Brigham) of 184,511 and nine clinical/registry cohorts totaling 7,850. Carriers of MYH7 variants presented with a more obstructive and arrhythmogenic phenotype, demonstrating higher odds of LVOT obstruction (pooled OR range: 1.95–4.30) and a 70% increased risk of incident atrial fibrillation (HR: 1.7, 95% CI: 1.1–2.6). In contrast, carriers of MYBPC3 variants, while often presenting later, faced a significantly elevated risk of progressive systolic dysfunction (adjusted HR: 2.53, 95% CI: 1.09–5.82). MYH7 was also associated with greater interventricular septal thickness (MD: 1.30 mm, 95% CI: 0.06–2.54). Substantial heterogeneity ( I 2 = 80.7%) was observed, reflecting real-world differences in phenotype ascertainment.
Conclusions
This analysis confirms that obstructive HCM follows mutation-specific clinical trajectories. Genotype provides critical prognostic insights, delineating an MYH7 driven path of early obstruction and arrhythmia from an MYBPC3 associated trajectory of long term systolic decline. These findings support the integration of genetic data into personalized surveillance strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Zitieren
APA
Li, Y., & Yu, J. (2026). Are clinical trajectories in obstructive hypertrophic cardiomyopathy mutation-specific? A systematic review and meta-analysis of MYH7 vs. MYBPC3. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1752303
Vancouver
Li Y, Yu J. Are clinical trajectories in obstructive hypertrophic cardiomyopathy mutation-specific? A systematic review and meta-analysis of MYH7 vs. MYBPC3. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1752303
BibTeX
@article{Li2026,
author = {Li, Yunqing and Yu, Jin},
title = {Are clinical trajectories in obstructive hypertrophic cardiomyopathy mutation-specific? A systematic review and meta-analysis of MYH7 vs. MYBPC3},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1752303}
}
EUVIMED